Literature DB >> 15094449

Development of 99mTc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig.

Etienne Garin1, Nicolas Noiret, Charles-Henri Malbert, Nicolas Lepareur, Alain Roucoux, Léontine Dazord, Sylvie Caulet-Maugendre, Bruno Turlin, Annick Moisan, Joseph Lecloirec, Jean-Yves Herry, Eveline Boucher, Jean-Lue Raoul, Patrick Bourguet.   

Abstract

BACKGROUND: We develop a method for the radiolabelling of Lipiodol with Tc, using a lipophilic complex, [99mTc-(S2CPh)(S3Ph)2], dissolved in Lipiodol (99mTc-SSS Lipiodol).
RESULTS: The labelling yield is high (96 +/- 0.8%), and the radiochemical purity satisfactory (92 +/- 2.6%). This labelling is reproducible and stable for up to 24 h in vitro. Studies carried out after injection into the hepatic artery of the healthy pig show that the biodistribution of 99mTc-SSS Lipiodol is comparable with that observed for 188Re Lipiodol.
MATERIALS AND METHODS: The 99mTc-SSS lipiodol was obtained after dissolving a chelating agent, previously labelled with 99mTc, in cold lipiodol. The radiochemical purity (RCP) of the labelling was checked immediately and at 24 h. The 99mTc-SSS lipiodol was injected into the hepatic artery of four healthy pigs for an ex-vivo biodistribution study. An autoradiographic study was performed in two cases.
CONCLUSIONS: Apart from the specific interest of a Lipiodol-bearing technetiated agent for carrying out dosimetric studies, the labelling of Lipiodol with 99mTc is a preliminary step towards the use of radiolabelling with the 188Re analogue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094449     DOI: 10.1097/00006231-200403000-00013

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.

Authors:  Kostas Delaunay; Julien Edeline; Yan Rolland; Nicolas Lepareur; Sophie Laffont; Xavier Palard; Christelle Bouvry; Samuel Le Sourd; Marc Pracht; Valérie Ardisson; Nicolas Noiret; Éric Bellissant; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-04       Impact factor: 9.236

2.  99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution.

Authors:  Sandrine Ballot; Nicolas Noiret; François Hindré; Benoît Denizot; Etienne Garin; Holisoa Rajerison; Jean-Pierre Benoit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

3.  Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs.

Authors:  E Garin; N Noiret; C Malbert; N Lepareur; A Roucoux; S Caulet-Maugendre; A Moisan; J Lecloirec; J Y Herry; P Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-23       Impact factor: 9.236

4.  (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

Authors:  Nicolas Lepareur; Valérie Ardisson; Nicolas Noiret; Etienne Garin
Journal:  Int J Mol Imaging       Date:  2012-02-22

5.  Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells.

Authors:  S Auletta; V Iodice; F Galli; N Lepareur; A Devillers; A Signore
Journal:  Contrast Media Mol Imaging       Date:  2018-10-25       Impact factor: 3.161

6.  Development of Biocompatible and Functional Polymeric Nanoparticles for Site-Specific Delivery of Radionuclides.

Authors:  Nicolas Lepareur; Loleh Leal E Costa; Maëva Bocqué; Clément Blondelle; Clément Ruello; Marie Desjulets; Nicolas Noiret; Sandrine Cammas-Marion
Journal:  Front Med (Lausanne)       Date:  2015-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.